Suchergebnisse

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm

Wall Street closed lower on Monday, pulled down by healthcare and industrial stocks. Investor sentiment remained cautious as concerns over escalating Middle East tensions, higher oil prices and

As demand for AI training and inference continues to outpace supply, companies with access to capital and the ability to deploy GPU infrastructure quickly stand to benefit the most. Nebius Group

Zions Bancorporation’s ZION second-quarter 2026 adjusted earnings of $1.74 per share surpassed the Zacks Consensus Estimate of $1.57. Moreover, the bottom line increased 10.1% from the year-ago

BOK Financial Corporation's BOKF second-quarter 2026 adjusted earnings of $2.59 per share surpassed the Zacks Consensus Estimate of $2.56. The bottom line jumped 18.3% from the prior-year quarter.

Zacks Investment Research has recently initiated coverage of KVH Industries, Inc. KVHI, assigning an "Outperform" recommendation to the company's shares. This bullish stance reflects the company's

KeyCorp’s KEY second-quarter 2026 earnings from continuing operations of 44 cents per share outpaced the Zacks Consensus Estimate of 42 cents. The bottom line reflected a 25.7% rise from the

MercadoLibre, Inc. MELI continues to deepen its ecosystem integration through its credit card business, which is emerging as a central driver of user engagement. During the first quarter of 2026

Novo Nordisk NVO and Eli Lilly LLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist tirzepatide as Mounjaro for type II

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 21:

Astronics Corporation ATRO: This aerospace and defense company has a Zacks Rank #1

Physical AI is turning into one of the market's hottest themes, and two lidar names sit right at its center— China's Hesai Group HSAI and San Francisco-based Ouster OUST. Hesai builds its own ASIC

Flexible Solutions International, Inc. FSI reported a sharp 35% year-over-year decline in second-quarter 2026 revenues to $7.4 million. The reason for the decline was primarily cited as a historical

Pfizer PFE will announce its second-quarter 2026 earnings on Aug. 4, and investors will be watching the performance of its oncology business closely, as the segment generates nearly 27% of the

Innodata Inc. INOD appears to be hitting its stride as accelerating adoption of Artificial Intelligence (AI) fuels demand for specialized data engineering, model evaluation and AI safety services

Quanta Services, Inc. PWR is strengthening its competitive position by focusing on execution certainty as customers undertake increasingly large and complex infrastructure projects. Utilities are